Watch a presentation by Ram May-Ron, Managing Partner, FreeMind Group. Ram presented during the 10th Annual Non-dilutive Funding Summit that took place in San Francisco on January 14, 2015. In his presentation Ram discussed the state of the non-dilutive funding market as it relates to industry and the Billions of dollars that are available. Ram also […]
The Non-Dilutive Funding Summit came together on January 14th, 2015 for the tenth consecutive year. The ~300 life science executives who attended the day long activities learned about Neuroscience Funding Opportunities related to the mission of the National Institute of Neurological Disorders and Stroke (NINDS) from Dr Rajesh Ranganathan, as well as a detailed description […]
With the recent Ebola outbreak in Western Africa and subsequent extensive media coverage and public concern, Federal Agencies are teaming together to support novel research in the fight to eradicate this deadly disease. In this webinar FreeMind experts will share insight into the Ebola funding space as well as describe in detail current funding opportunities […]
[vc_row][vc_column width=”1/1″][pt_heading h=”H1″ heading=”Non-Dilutive Funding Summit” text_align=”align-left”][pt_marginblock measure=”px”]50[/pt_marginblock][pt_leadtext text_align=”align-left”] Join over 400 life science industry leaders in a full day of non-dilutive funding activities at the 10th Annual Non-dilutive Funding Summit, taking place on Wednesday January 14th, 2015 at the Nikko Hotel San Francisco. The summit is proud to host Dr. Rajesh Ranganathan, the Director […]
Registration is a multi-step process that can take 8 weeks or more and MUST be completed before the submission deadline. Organizations must be registered with the System for Award Management (SAM), Grants.gov and eRA Commons. The registration process is not sequential. As soon as an organization has obtained its DUNS number, it can begin registering […]
SBIR/STTR awards account for over $780,000,000 awarded per year by NIH alone to industry. These are excellent sources of funding aimed at promoting R&D activities of small businesses as well as collaborations with Academics. SBIR/STTRs differ from traditional NIH mechanisms in that they are highly product driven and ultimately are seeking commercialization of novel therapies, […]
In a world in which both medical diagnostics and therapies are shifting towards minimally invasive technologies, it is not surprising that steadily increasing non-dilutive funding is available for innovative medical device companies. The scope of funding support covers the entire R&D cycle, from early stage exploratory and discovery work all the way to late stage […]
Assembling a budget for your grant is typically the last item to be addressed. Reason being that the figures you are suggesting must reflect the work you are proposing to complete. That said, simply stating the cost per item is hardly enough, and a properly constructed justification is mandatory and weighs heavily on approval of […]
NINDS has just issued a number of funding opportunities covering separately the development of biologics, small molecules and devices in a cooperative manner with the issuing institute (U-Mechanism). This serves a major paradigm shift in NINDS funding. Further, within the non-dilutive funding space one can find pockets of money in the billions of dollars directed […]
NIH alone awards roughly $5.8B annually to Cancer related R&D grants and contracts. The scope of funding support covers much of the R&D cycle with an emphasis on pre-clinical work, and may cover clinical stage activities as well. In this webinar in the series of summer educational webinars, FreeMind experts discuss key cancer related opportunities, […]